| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yanlin Wang, Matthew Harlin, Frank Larsen, Xiaofeng Wang, Wansu Park, Benjamin Rich, Jogarao V Gobburu, Arash Raoufini. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. Clinical pharmacology in drug development. 2024-04-11. PMID:38602057. |
population pharmacokinetics and dosing simulations for aripiprazole 2-month ready-to-use long-acting injectable in adult patients with schizophrenia or bipolar i disorder. |
2024-04-11 |
2024-04-13 |
Not clear |
| Yanlin Wang, Matthew Harlin, Frank Larsen, Xiaofeng Wang, Wansu Park, Benjamin Rich, Jogarao V Gobburu, Arash Raoufini. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. Clinical pharmacology in drug development. 2024-04-11. PMID:38602057. |
a ready-to-use (rtu) long-acting injectable (lai) formulation of aripiprazole monohydrate for administration once every 2 months, available in 960 mg (ari 2mrtu 960) or 720 mg doses, has been developed for the treatment of schizophrenia or bipolar i disorder. |
2024-04-11 |
2024-04-13 |
Not clear |
| Miquel Bioque, María José Moreno, Susana Gómez-Lus, María Isabel Ramo. Clinical Experience on the Use of a Single-day, Two-injection Start Initiation Regimen of Aripiprazole Once Monthly in Patients With Schizophrenia in Spain: SaTISfy Study. Journal of psychiatric practice. vol 30. issue 2. 2024-03-25. PMID:38526396. |
clinical experience on the use of a single-day, two-injection start initiation regimen of aripiprazole once monthly in patients with schizophrenia in spain: satisfy study. |
2024-03-25 |
2024-03-27 |
Not clear |
| Mark G A Opler, Amy Claxton, James McGrory, Sabina Gasper, Meihua Wang, Sergey Yagod. Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc Analysis. Innovations in clinical neuroscience. vol 21. issue 1-3. 2024-03-18. PMID:38495608. |
functioning and cognition in patients with schizophrenia after initiating treatment with aripiprazole lauroxil: secondary outcomes and post hoc analysis. |
2024-03-18 |
2024-03-20 |
Not clear |
| Mark G A Opler, Amy Claxton, James McGrory, Sabina Gasper, Meihua Wang, Sergey Yagod. Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc Analysis. Innovations in clinical neuroscience. vol 21. issue 1-3. 2024-03-18. PMID:38495608. |
we assessed daily/social functioning and cognition in stable patients with schizophrenia who switched to the long-acting injectable (lai) antipsychotic aripiprazole lauroxil (al). |
2024-03-18 |
2024-03-20 |
Not clear |
| Cun Zhang, Lei Jiang, Ke Hu, Liang Chen, Yi-Jia Zhang, Hao-Zhe Shi, Su-Mei He, Xiao Chen, Dong-Dong Wan. Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients. Neuropsychiatric disease and treatment. vol 20. 2024-03-12. PMID:38469209. |
effects of aripiprazole on olanzapine population pharmacokinetics and initial dosage optimization in schizophrenia patients. |
2024-03-12 |
2024-03-14 |
Not clear |
| Leslie Citrome, Sergey Yagoda, Ilda Bidollari, Meihua Wan. Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial. The Journal of clinical psychiatry. vol 85. issue 1. 2024-02-28. PMID:38416865. |
safety and tolerability of starting aripiprazole lauroxil with aripiprazole lauroxil nanocrystal dispersion in 1 day followed by aripiprazole lauroxil every 2 months using paliperidone palmitate monthly as an active control in patients with schizophrenia: a post hoc analysis of a randomized controlled trial. |
2024-02-28 |
2024-03-02 |
Not clear |
| Sitong Feng, Sisi Zheng, Linrui Dong, Ziyan Li, Hong Zhu, Shanshan Liu, Xue Li, Yanzhe Ning, Hongxiao Ji. Effects of aripiprazole on resting-state functional connectivity of large-scale brain networks in first-episode drug-naïve schizophrenia patients. Journal of psychiatric research. vol 171. 2024-02-03. PMID:38309211. |
effects of aripiprazole on resting-state functional connectivity of large-scale brain networks in first-episode drug-naïve schizophrenia patients. |
2024-02-03 |
2024-02-06 |
Not clear |
| Sitong Feng, Sisi Zheng, Linrui Dong, Ziyan Li, Hong Zhu, Shanshan Liu, Xue Li, Yanzhe Ning, Hongxiao Ji. Effects of aripiprazole on resting-state functional connectivity of large-scale brain networks in first-episode drug-naïve schizophrenia patients. Journal of psychiatric research. vol 171. 2024-02-03. PMID:38309211. |
aripiprazole modulates functional connectivity (fc) between several brain regions in first-episode schizophrenia patients, contributing to improvement in clinical symptoms. |
2024-02-03 |
2024-02-06 |
Not clear |
| Sitong Feng, Sisi Zheng, Linrui Dong, Ziyan Li, Hong Zhu, Shanshan Liu, Xue Li, Yanzhe Ning, Hongxiao Ji. Effects of aripiprazole on resting-state functional connectivity of large-scale brain networks in first-episode drug-naïve schizophrenia patients. Journal of psychiatric research. vol 171. 2024-02-03. PMID:38309211. |
however, the effects of aripiprazole on abnormal connections among extensive brain networks in schizophrenia patients remain unclear. |
2024-02-03 |
2024-02-06 |
Not clear |
| Sitong Feng, Sisi Zheng, Linrui Dong, Ziyan Li, Hong Zhu, Shanshan Liu, Xue Li, Yanzhe Ning, Hongxiao Ji. Effects of aripiprazole on resting-state functional connectivity of large-scale brain networks in first-episode drug-naïve schizophrenia patients. Journal of psychiatric research. vol 171. 2024-02-03. PMID:38309211. |
before aripiprazole treatment, schizophrenia patients showed decreased fc of extensive brain networks compared to healthy controls. |
2024-02-03 |
2024-02-06 |
Not clear |
| Sitong Feng, Sisi Zheng, Linrui Dong, Ziyan Li, Hong Zhu, Shanshan Liu, Xue Li, Yanzhe Ning, Hongxiao Ji. Effects of aripiprazole on resting-state functional connectivity of large-scale brain networks in first-episode drug-naïve schizophrenia patients. Journal of psychiatric research. vol 171. 2024-02-03. PMID:38309211. |
taken together, these findings have revealed the effects of aripiprazole on fc in large-scale networks in schizophrenia patients, which could provide new insight on interpreting symptom improvement in sch. |
2024-02-03 |
2024-02-06 |
Not clear |
| Ludovic Samalin, Ludivine Boudieu, Pierre Michel Llorc. Evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar I disorder in adults. Expert review of neurotherapeutics. 2024-02-01. PMID:38299536. |
evaluating the efficacy and safety of the currently available once-every-two months long-acting injectable formulations of aripiprazole for the treatment of schizophrenia or as a maintenance monotherapy for bipolar i disorder in adults. |
2024-02-01 |
2024-02-03 |
Not clear |
| Juan José Fernández-Miranda, Silvia Díaz-Fernández, Francisco Javier Cepeda-Piorno, Francisco López-Muño. Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes. Biomedicines. vol 12. issue 1. 2024-01-23. PMID:38255270. |
an observational, prospective, one-year follow-up study was carried out with patients (n = 68) with severe schizophrenia treated with paliperidone three-month (pp3m) or aripiprazole one-month (arim). |
2024-01-23 |
2024-01-25 |
human |
| Florian W Adraoui, Kenza Hettak, Geoffrey Viardot, Magali Alix, Sabrina Guiffard, Benoît Meot, Philippe L'Hostis, Anne Maurin, Eric Delpy, Christophe Drieu La Rochelle, Kevin Carvalh. Differential Effects of Aripiprazole on Electroencephalography-Recorded Gamma-Band Auditory Steady-State Response, Spontaneous Gamma Oscillations and Behavior in a Schizophrenia Rat Model. International journal of molecular sciences. vol 25. issue 2. 2024-01-23. PMID:38256109. |
differential effects of aripiprazole on electroencephalography-recorded gamma-band auditory steady-state response, spontaneous gamma oscillations and behavior in a schizophrenia rat model. |
2024-01-23 |
2024-01-25 |
rat |
| Mehdi Akbari, Shiva Jamshidi, Sonay Sheikhi, Farhad Alijani, Parsa Kafshchi, David Taylo. Aripiprazole and its adverse effects in the form of impulsive-compulsive behaviors: A systematic review of case reports. Psychopharmacology. 2024-01-16. PMID:38227009. |
aripiprazole is an efficacious treatment for both the positive and negative symptoms of schizophrenia and is also commonly used as a mood stabilizer. |
2024-01-16 |
2024-01-18 |
Not clear |
| Sanya Sharma, Ajeet Sidana, Shivangi Mehta, Manoj Kumar Baja. Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia. Indian journal of psychiatry. vol 65. issue 10. 2023-12-19. PMID:38108052. |
comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia. |
2023-12-19 |
2023-12-21 |
Not clear |
| Bernhard T Baun. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy. Current medical research and opinion. 2023-11-24. PMID:37999650. |
aripiprazole 2-month ready-to-use 960 mg (ari 2mrtu): review of its possible role in schizophrenia therapy. |
2023-11-24 |
2023-11-29 |
Not clear |
| Bernhard T Baun. Aripiprazole 2-month ready-to-use 960 mg (Ari 2MRTU): review of its possible role in schizophrenia therapy. Current medical research and opinion. 2023-11-24. PMID:37999650. |
taken together, since aripiprazole may be a good treatment choice for many patients based on its favorable safety and tolerability profile, and given the advantages of lai treatment over oral treatment and the advantages of reduced dosing frequency, ari 2mrtu 960 may become an important treatment option for many clinically stable patients with schizophrenia. |
2023-11-24 |
2023-11-29 |
Not clear |
| Christoph U Correll, Andreas Brieden, Wolfgang Janetzk. Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly. Schizophrenia (Heidelberg, Germany). vol 9. issue 1. 2023-11-07. PMID:37935711. |
symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly. |
2023-11-07 |
2023-11-20 |
Not clear |